PreComb’s technology is poised to transform precision oncology by enabling the rapid discovery and delivery of personalized cancer treatments. With its proprietary screening and automation technology, the Swis biotech company speeds up the drug discovery process and brings new therapies to patients faster than ever before. In combination with its advanced digitalization framework, PreComb unlocks insights from massive amounts of clinical data, empowering clinicians to make the right treatment decisions.
- For Pharma Companies: The platform accelerates drug discovery by enabling the testing of multiple molecules within drug candidates to identify the most effective ones. This approach significantly reduces development timelines and costs while improving clinical trial success rates.
- For Patients and Oncologists: The platform provides personalized therapies tailored to each patient’s unique cancer profile, helping to identify the right treatment faster. By enabling evidence-based decisions, it reduces guesswork, minimizes side effects, and improves outcomes for every cancer case.
PreComb has successfully developed and deployed its fully automated 3DTwin Profiler prototype at the University Hospital Zurich in 2023, advancing precision oncology with hands-free 3DTwin profiling assays. Jens Kelm, Chief Scientific Officer and co-founder of PreComb, shared: “I am eager to advance the technology further towards patient applications, following the successful completion of technological and clinical validation in collaboration with our clinical partners over the past three years.”
With the successful completion of its Series A funding, PreComb is now poised to commercialize its technology and scale operations. The company aims to:
- Engage pharmaceutical partners to integrate the platform into oncology R&D.
- Collaborate with oncologists and researchers to implement the solution in clinical settings.
The Series A funding round was led by Koodos, a prominent investment fund specializing in transformative biotech ventures. Nathaniel Hutley, Director at Koodos, transmitted his excitement about the partnership:
“Koodos is proud to join PreComb at this decisive stage in their journey. We are deeply committed to supporting companies that redefine industry standards, and PreComb’s innovative approach to personalized oncology perfectly aligns with our values. We look forward to working closely with the team and contributing to their continued success.”
(Press release / SK)